The same could happen in the transition from premalignant to malignant cells in humans, explaining why in DLBCL with TRAF2/3 mutations the canonical NF-ĸB pathway is often coactivated with the non-canonical one. Here, TRAF2 is linked to diffuse large B-cell lymphoma.